Cyclo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 8
- Market Cap
- -
- Introduction
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05607615
- Locations
- 🇺🇸
Access Research Institute, Brooksville, Florida, United States
🇺🇸Charter Research, Winter Park, Florida, United States
🇺🇸Tandem/Clincloud, LCC, Marrero, Louisiana, United States
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT04860960
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸University of Florida, Jacksonville, Florida, United States
🇺🇸Emory, Atlanta, Georgia, United States
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- Drug: Hydroxypropyl-β-cyclodextrin
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03893071
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
- Conditions
- Late Onset Alzheimer Disease
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Registration Number
- NCT03624842
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)
- Conditions
- Niemann-Pick Disease, Type C1
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Cyclo Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02939547
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
- Prev
- 1
- 2
- Next
News
Rafael Holdings Completes $25 Million Rights Offering to Fund Trappsol Cyclo Phase 3 Trial for Rare Disease
Rafael Holdings successfully completed a $25 million rights offering in June 2025, with CEO Howard Jonas backstopping the majority of unsubscribed shares through a private placement.
Trappsol Cyclo Shows Promise in Stabilizing or Improving Niemann-Pick Disease Type C1 in Young Patients
Preliminary data from Cyclo Therapeutics' TransportNPC trial shows that 87% of patients under three years old with Niemann-Pick Disease Type C1 (NPC1) demonstrated stabilization or improvement after 24 weeks of Trappsol Cyclo treatment.